Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity - K. H. Williams, A. J. Viera de Ribeiro, E. Prakoso, A. S. Veillard, N. A. Shackel, Y. Bu, B. Brooks, E. Cavanagh, J. Raleigh, S. V. McLennan, G. W. McCaughan, W. W. Bachovchin, F. M. Keane, A. Zekry, S. M. Twigg - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Diabetes Research and Clinical Practice, 3(108), p. 466-472, 2015

DOI: 10.1016/j.diabres.2015.02.024

Links

Elsevier

Tools

Export citation

Search in Google Scholar

Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity

Journal article published in 2015 by K. H. Williams, A. J. Viera de Ribeiro, E. Prakoso, A. S. Veillard, N. A. Shackel, Y. Bu, B. Brooks, E. Cavanagh, J. Raleigh, S. V. McLennan, G. W. McCaughan, W. W. Bachovchin, F. M. Keane, A. Zekry, S. M. Twigg and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO